株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

次世代癌診断:技術および世界市場

Next-Generation Cancer Diagnostics: Technologies and Global Markets

発行 BCC Research 商品コード 180727
出版日 ページ情報 英文 274 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: BCC Research社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
次世代癌診断:技術および世界市場 Next-Generation Cancer Diagnostics: Technologies and Global Markets
出版日: 2014年08月31日 ページ情報: 英文 274 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

2013年、世界の次世代癌診断の市場は16億ドルの規模を記録し、2014年には18億ドルに達する見通しです。さらに、その後の5年間は42.6%のCAGRを記録し、2019年には100億ドルの規模に成長する見通しです。

当レポートでは、次世代癌診断市場の概要と、DNA、タンパク質マイクロアレイ、ラボオンチップ、DNAシーケンシングなどの技術プラットフォームに注目しながら、世界市場の動向と2015年までの予測、競合する企業のプロファイルと特許分析などを交え、概略下記の構成でお届けします。

第1章 イントロダクション

第2章 サマリー

第3章 概要

  • イントロダクション
  • 次世代癌診断の市場潜在性
  • 成長促進因子
  • プラットフォーム
  • 製品ライフサイクル
  • 業界

第4章 次世代癌診断技術

  • 診断の概要
  • 技術概要
  • 遺伝子解析
  • 遺伝子解析技術
  • エピジェネティクス解析
  • 循環腫瘍細胞分析
  • プロテオーム解析
  • 次世代癌診断技術プラットフォーム

第5章 次世代癌診断の応用

  • イントロダクション
  • バイオマーカーの発見による成長の推進
  • 新しい診断アッセイの臨床での受容
  • 分子診断
  • 次世代診断の状況:適応症別
  • 薬検査
  • 次世代癌診断検査のサマリー

第6章 業界動向

  • 買収
  • 戦略的提携
  • 循環腫瘍細胞診断業界
  • DNAマイクロアレイ診断業界
  • 次世代シーケンシング器具業界
  • 臨床ラボ用次世代シーケンシング業界
  • ラボオンチップ(LOAC)次世代癌診断業界
  • RT-PCR次世代癌診断業界

第7章 次世代癌診断市場

  • 産業成長の牽引因子
  • 市場:サマリー
  • 市場:技術フォーマット別
  • 市場:診断機能別
  • 主な適応症の市場:技術プラットフォーム別
  • 次世代癌診断市場:地域別

第8章 特許

第9章 企業プロファイル

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: BIO081B

BCC Research estimates the global market for next generation cancer diagnostic as $1.6 billion in 2013. This indication is expected to reach $1.8 billion in 2014 and $10 billion in 2019, registering a compound annual growth (CAGR) of 42.6% over the next five years.

This report provides: An overview of the global market for next generation cancer diagnostics and related technologies. Analyses of global market trends, with data from 2013, estimates for 2014, and projections of compound annual growth rates (CAGRs) through 2019. Analyses of the diagnostics market by cancer indication (e.g., breast, colorectal, prostate, etc.), by type of analysis (e.g., gene expression, genotyping, proteomic, etc.), and by diagnostic function (e.g., screening/early detection, prognosis, monitoring/recurrence, and companion diagnostic). Examination of each technology format to determine its market status, impact on future market segments, and projected growth through the forecast period. Discussion on factors influencing the market including cancer diagnostics needs, regulatory trends, industry structure, and patent statuses. Assessments of the major next generation formats that are likely to become commercialized within the next five years. Profiles of companies in the industry as well as a look at corporate alliances.

image1

REPORT SCOPE

SCOPE AND FORMAT

The study scope includes the major next generation formats that are likely to become commercialized within the next five years. Each technology format is analyzed to determine its market status, impact on future market segments and projected growth from 2014 through 2019. Technology issues and forces driving the market are discussed.

Influencing factors, including cancer diagnostic needs, regulatory trends, industry structure and patent status are also discussed.

BCC Research examines companies in the industry, corporate alliances and assay consumption by indication. More than 130 companies participating in the industry are profiled in this report.

ANALYST'S CREDENTIALS

John Bergin is the author of previous BCC Research biotechnology reports titled Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics; Global Biochip Markets: Microarrays and Lab-on-a-Chip; RNA Interference in the Post-Genomics Era: Markets and Technologies; DNA Sequencing: Emerging Technologies and Applications; Biologic Imaging Reagents: Technologies and Global Markets; and Synthetic Biology: Emerging Global Markets.

Mr. Bergin has held business development, sales and marketing positions with a Fortune 500 advanced materials company, as well as executive management positions with an emerging nanotechnology company. Mr. Bergin holds a BS degree in Chemistry, an MS degree in Biotechnology and a Masters of Business Administration.

Table of Contents

CHAPTER 1 INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • INTENDED AUDIENCE
  • SCOPE AND FORMAT
  • METHODOLOGY
  • INFORMATION SOURCES
  • RELATED BCC RESEARCH REPORTS
  • ANALYST'S CREDENTIALS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 SUMMARY

  • SUMMARY TABLE GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY INDICATION, 2013-2019 ($ MILLIONS)

CHAPTER 3 OVERVIEW

  • INTRODUCTION
  • TABLE 1 REPORT SCOPE
  • NEXT GENERATION CANCER DIAGNOSTIC MARKETING POTENTIAL
  • TABLE 2 GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 ($ MILLIONS)
  • DRIVING FORCES
  • TABLE 3 CANCER DIAGNOSTIC MARKET DRIVING FORCES, THROUGH 2019
  • PLATFORMS
  • PRODUCT LIFECYCLE STATUS
  • TABLE 4 DIAGNOSTIC PRODUCT LIFECYCLE STATUS, 2014
  • INDUSTRY
  • TABLE 5 NEXT GENERATION CANCER DIAGNOSTIC INDUSTRY, 2014

CHAPTER 4 NEXT GENERATION CANCER DIAGNOSTIC TECHNOLOGIES

  • DIAGNOSTICS OVERVIEW
  • TABLE 6 DIAGNOSTIC MARKET SEGMENTS
  • TABLE 7 NEXT GENERATION CANCER DIAGNOSTIC PLATFORMS, 2014-2019
  • TECHNOLOGY OVERVIEW
  • TABLE 8 ANALYSIS PLATFORMS AND BIOMARKER TYPES
  • GENETIC ANALYSIS
  • FIGURE 1 DNA, MRNA AND GENETIC VARIATION
  • GENETIC ANALYSIS TECHNOLOGIES
  • TABLE 9 SCOPE OF KEY GENOMIC ANALYSIS TECHNOLOGIES, 2014
  • TABLE 10 GENETIC ANALYSIS TECHNOLOGY PLATFORM COMPARISON
  • EPIGENETIC ANALYSIS
    • PARADIGM CHANGE
    • TABLE 11 EPIGENETICS WITHIN THE MOLECULAR BIOLOGY PARADIGM
    • DNA METHYLATION ANALYSIS
    • FIGURE 2 EPIGENETIC CHANGES TO DNA AFFECTING GENE EXPRESSION
  • CIRCULATING TUMOR CELL ANALYSIS
  • TABLE 12 CIRCULATING TUMOR CAPTURE METHODS
  • TABLE 13 CIRCULATING TUMOR CAPTURE IDENTIFICATION METHODS
  • PROTEOMIC ANALYSIS
  • NEXT GENERATION CANCER DIAGNOSTIC TECHNOLOGY PLATFORMS
    • DNA MICROARRAYS
    • TABLE 14 DNA MICROARRAY TECHNOLOGIES
    • PROTEIN MICROARRAYS
    • TABLE 15 PROTEIN MICROARRAY PLATFORMS
    • LAB-ON-A-CHIP
    • TABLE 16 LAB-ON-A-CHIP TYPES
      • In Vitro Proteomics
      • Electrophoresis on a Chip
      • Structural Proteomics
      • PCR on a Chip
      • Immunoassays on a Chip
    • REAL-TIME POLYMERASE CHAIN REACTION
    • TABLE 17 CONVENTIONAL END-POINT REAL-TIME POLYMERASE CHAIN REACTION DETECTION PROBLEMS
    • TABLE 18 REAL-TIME POLYMERASE CHAIN REACTION CANCER DIAGNOSTIC APPLICATIONS
    • NEXT GENERATION SEQUENCING PLATFORMS
    • TABLE 19 NEXT GENERATION SEQUENCING TECHNOLOGIES
    • TABLE 20 ROCHE NEXT GENERATION SEQUENCING WORKFLOW, 2014
    • TABLE 21 ILLUMINA NEXT GENERATION SEQUENCING WORKFLOW, 2014
    • TABLE 22 LIFE TECHNOLOGIES NEXT GENERATION SEQUENCING WORKFLOW, 2014
    • BENCHTOP SEQUENCERS
    • TABLE 23 BENCHTOP SEQUENCER PLATFORMS, 2014
    • NEXT GENERATION SEQUENCING IN THE CLINICAL SETTING
    • TABLE 24 GENETIC TESTING EVOLUTION
    • TABLE 25 KEY NEAR- TO MID-TERM SEGMENTS FOR NEXT GENERATION SEQUENCING DIAGNOSTICS, 2014-2019

CHAPTER 5 NEXT GENERATION CANCER DIAGNOSTIC APPLICATIONS

  • INTRODUCTION
  • TABLE 26 NEXT GENERATION DIAGNOSTIC PARADIGM SHIFT, 2000-2020
  • BIOMARKER DISCOVERY DRIVING GROWTH
  • TABLE 27 BIOMARKERS USED IN NEXT GENERATION DIAGNOSTICS
  • CLINICAL ACCEPTANCE OF A NEW DIAGNOSTIC ASSAY
  • TABLE 28 DNA MICROARRAY DIAGNOSTIC TEST ADOPTION RATE
  • MOLECULAR DIAGNOSTICS
    • INTRODUCTION
    • MARKET PENETRATION CHALLENGES
    • TABLE 29 COMPARISON OF DNA-BASED MDX PLATFORMS
    • TABLE 30 FACTORS AFFECTING PENETRATION OF NEXT GENERATION FORMATS INTO THE MDX MARKET
    • MARKET SEGMENTS
    • TEST SENSITIVITY AND SPECIFICITY
    • FIGURE 3 SENSITIVITY AND SPECIFICITY
    • REGULATORY STATUS
  • STATUS OF NEXT GENERATION DIAGNOSTICS BY INDICATION
    • CANCER OVERVIEW
    • TABLE 31 U.S. INCIDENCE AND DEATHS FOR SELECTED CANCERS, 2010 AND 2013 (NUMBER)
    • BLADDER CANCER
    • TABLE 32 BLADDER CANCER NEXT GENERATION DIAGNOSTIC TESTS, 2014
    • BRAIN CANCER
    • TABLE 33 BRAIN CANCER NEXT GENERATION DIAGNOSTIC TESTS, 2014
    • BREAST CANCER
    • Breast Cancer Screening
    • Prognosis and Pharmacogenetics Tests
    • TABLE 34 U.S. ANNUAL BREAST CANCER TREATMENT DECISIONS BY CANCER CLASSIFICATION, 2014 (NUMBER)
    • Breast Cancer MDx Platforms
    • TABLE 35 BREAST CANCER MDX TECHNOLOGY PLATFORMS, 2014
    • Status of Next generation Breast Cancer Tests
    • TABLE 36 NEXT GENERATION BREAST CANCER TESTS, 2014
      • Breast Cancer Early Detection and Screening Tests
      • Breast Cancer Risk Tests
      • Response to Chemotherapy, Recurrence Probability and Subtyping
      • CERVICAL CANCER
      • TABLE 37 NEXT GENERATION HUMAN PAPILLOMA VIRUS AND CERVICAL CANCER TESTS, 2014
      • COLORECTAL CANCER
      • Conventional Colorectal Cancer Screening Tests
      • TABLE 38 COLORECTAL CANCER SCREENING AND DIAGNOSTIC TESTS, 2014
      • Next Generation Colorectal Cancer Diagnostics Tests
      • TABLE 39 NEXT GENERATION DIAGNOSTIC TESTS FOR COLORECTAL CANCER, 2014
    • CANCER OF UNKNOWN PRIMARY
    • TABLE 40 CANCER OF UNKNOWN PRIMARY NEXT GENERATION DIAGNOSTIC TESTS, 2014
    • GASTRIC CANCER
    • TABLE 41 GASTRIC AND STOMACH CANCER NEXT GENERATION DIAGNOSTIC TESTS, 2014
    • KIDNEY CANCER
    • TABLE 42 NEXT GENERATION KIDNEY CANCER DIAGNOSTIC TESTS, 2014
    • LEUKEMIA
    • TABLE 43 NEXT GENERATION LEUKEMIA AND MYELOMA DIAGNOSTIC TESTS, 2014
    • LIVER CANCER
    • TABLE 44 NEXT GENERATION LIVER CANCER DIAGNOSTIC TESTS, 2014
    • LUNG CANCER
    • TABLE 45 FIVE-YEAR SURVIVAL RATES FOR NON-SMALL CELL LUNG CANCER, 2014 (%)
    • TABLE 46 NEXT GENERATION LUNG CANCER DIAGNOSTIC TESTS, 2014
    • LYMPHOMAS
    • TABLE 47 NEXT GENERATION LYMPHOMA CANCER DIAGNOSTIC TESTS, 2014
    • MELANOMA
    • TABLE 48 NEXT GENERATION MELANOMA DIAGNOSTIC TESTS, 2014
    • OVARIAN CANCER
    • TABLE 49 OVARIAN CANCER EARLY SCREENING TESTS
    • TABLE 50 NEXT GENERATION OVARIAN CANCER DIAGNOSTIC TESTS, 2014
    • PAN-CANCER
    • TABLE 51 NEXT GENERATION PAN-CANCER DIAGNOSTIC TESTS, 2014
    • PANCREATIC CANCER
    • TABLE 52 NEXT GENERATION PANCREATIC CANCER DIAGNOSTIC TESTS, 2014
    • PROSTATE CANCER
    • TABLE 53 NEXT GENERATION PROSTATE CANCER DIAGNOSTIC TESTS, 2014
    • THYROID CANCER
    • TABLE 54 NEXT GENERATION THYROID CANCER DIAGNOSTIC TESTS, 2014
  • NEXT GENERATION CANCER DIAGNOSTIC TEST SUMMARY
  • TABLE 55 NEXT GENERATION DIAGNOSTIC TEST SUMMARY BY INDICATION AND TECHNOLOGY, 2014

CHAPTER 6 INDUSTRY DYNAMICS

  • ACQUISITIONS
  • TABLE 56 ACQUISITIONS IN NEXT GENERATION CANCER DIAGNOSTICS INDUSTRY, 2012-2014
  • STRATEGIC ALLIANCES
  • TABLE 57 NEXT GENERATION CANCER DIAGNOSTIC STRATEGIC ALLIANCES, 2012-2014
  • CIRCULATING TUMOR CELL DIAGNOSTIC INDUSTRY
  • TABLE 58 CIRCULATING TUMOR CELL INDUSTRY, 2014
  • DNA MICROARRAY DIAGNOSTIC INDUSTRY
  • TABLE 59 DNA MICROARRAY INDUSTRY, 2014
  • NEXT GENERATION SEQUENCING INSTRUMENT INDUSTRY
  • TABLE 60 NEXT GENERATION SEQUENCING INSTRUMENT COMPANIES: COMMERCIAL PHASE, 2014
  • CLINICAL LABORATORY NEXT GENERATION SEQUENCING INDUSTRY
  • TABLE 61 LEADING U.S. CLINICAL LABORATORY IMPROVEMENT AMENDMENTS LABORATORIES WITH NEXT-GENERATION SEQUENCING DIAGNOSTICS, 2014
  • LAB-ON-A-CHIP NEXT GENERATION CANCER DIAGNOSTIC INDUSTRY
  • TABLE 62 NEXT GENERATION LAB-ON-A-CHIP CANCER DIAGNOSTIC INDUSTRY, 2014
  • RT-PCR NEXT GENERATION CANCER DIAGNOSTIC INDUSTRY
  • TABLE 63 NEXT GENERATION RT-PCR CANCER DIAGNOSTIC INDUSTRY, 2014

CHAPTER 7 NEXT GENERATION CANCER DIAGNOSTIC MARKETS

  • INDUSTRY GROWTH DRIVING FORCES
  • TABLE 64 CANCER DIAGNOSTIC MARKET DRIVING FORCES, 2014-2019
    • LIFE SCIENCE RESEARCH AND DEVELOPMENT FUNDING GROWTH
    • TARGETED MEDICINE DEVELOPMENT
    • EARLY CANCER DETECTION DEMAND
    • AGING POPULATIONS IN DEVELOPED REGIONS OF THE WORLD
    • INNOVATIVE DIAGNOSTIC TESTING FORMAT DEMAND
    • ONGOING DISCOVERIES IN GENOMICS
    • GENE AND SINGLE NUCLEOTIDE POLYMORPHISM DISEASE ASSOCIATION DISCOVERY
  • MARKET SUMMARY
    • MARKET BY TECHNOLOGY PLATFORM
    • TABLE 65 GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 ($ MILLIONS)
    • MARKET BY ANALYSIS TYPE
    • TABLE 66 GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY ANALYSIS TYPE, THROUGH 2019 ($ MILLIONS)
    • MARKET BY INDICATION
    • TABLE 67 GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
      • Bladder Cancer
      • Brain Cancer
      • Breast Cancer
      • Cervical Cancer
      • Colorectal Cancer
      • Cancer of Unknown Primary
      • Gastric Cancer
      • Kidney Cancer
      • Leukemia
      • Liver Cancer
      • Lung Cancer
      • Lymphoma
      • Melanoma
      • Ovarian Cancer
      • Pan-Cancer
      • Pancreatic Cancer
      • Prostate Cancer
      • Thyroid Cancer
    • MARKET BY DIAGNOSTIC FUNCTION
    • TABLE 68 GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY FUNCTION, THROUGH 2019 ($ MILLIONS)
  • MARKETS BY TECHNOLOGY FORMAT
    • DNA MICROARRAY MARKET
    • TABLE 69 GLOBAL DNA MICROARRAY CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
    • PROTEIN MICROARRAY MARKET
    • TABLE 70 GLOBAL PROTEIN MICROARRAY CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
    • LAB-ON-A-CHIP MARKET
    • TABLE 71 GLOBAL LAB-ON-A-CHIP CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
    • RT-PCR MARKET
    • TABLE 72 GLOBAL RT-PCR CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
    • NEXT GENERATION SEQUENCING MARKET
    • TABLE 73 GLOBAL NEXT GENERATION SEQUENCING CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
    • NEXT GENERATION CAPTURE MARKET
    • TABLE 74 GLOBAL NEXT GENERATION CAPTURE CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
    • MULTIPLEX CONVENTIONAL MARKET
    • TABLE 75 GLOBAL MULTIPLEX CONVENTIONAL CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
  • MARKETS BY DIAGNOSTIC FUNCTION
    • RISK MARKET
    • TABLE 76 GLOBAL NEXT GENERATION CANCER RISK MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
    • SCREENING MARKET
    • TABLE 77 GLOBAL NEXT GENERATION CANCER SCREENING MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
    • PROGNOSTIC MARKET
    • TABLE 78 GLOBAL NEXT GENERATION CANCER PROGNOSTIC MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
    • MONITORING MARKET
    • TABLE 79 GLOBAL NEXT GENERATION CANCER MONITORING MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
    • COMPANION DIAGNOSTIC MARKET
    • TABLE 80 GLOBAL NEXT GENERATION CANCER COMPANION DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
  • MARKETS FOR KEY INDICATIONS BY TECHNOLOGY PLATFORM
    • BREAST CANCER MARKET
    • TABLE 81 GLOBAL NEXT GENERATION BREAST CANCER DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 ($ MILLIONS)
    • CERVICAL CANCER MARKET
    • TABLE 82 GLOBAL NEXT GENERATION CERVICAL CANCER DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 ($ MILLIONS)
    • COLORECTAL CANCER MARKET
    • TABLE 83 GLOBAL NEXT GENERATION COLORECTAL CANCER DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 ($ MILLIONS)
    • CANCER OF UNKNOWN PRIMARY (CUP) MARKET
    • TABLE 84 GLOBAL NEXT GENERATION CANCER OF UNKNOWN PRIMARY (CUP) DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 ($ MILLIONS)
    • LEUKEMIA MARKET
    • TABLE 85 GLOBAL NEXT GENERATION LEUKEMIA DIAGNOSTIC MARKET BY TECHNOLOGY FORMAT, THROUGH 2015 ($ MILLIONS)
    • LUNG CANCER MARKET
    • TABLE 86 GLOBAL NEXT GENERATION LUNG CANCER DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 ($ MILLIONS)
    • LYMPHOMA MARKET
    • TABLE 87 GLOBAL NEXT GENERATION LYMPHOMA DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 ($ MILLIONS)
    • PAN-CANCER MARKET
    • TABLE 88 GLOBAL NEXT GENERATION PAN-CANCER DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 ($ MILLIONS)
    • TABLE 89 GENOME COVERAGE OF REPRESENTATIVE NEXT GENERATION SEQUENCING PAN-CANCER TESTS, 2014
    • PROSTATE CANCER MARKET
    • TABLE 90 GLOBAL NEXT GENERATION PROSTATE CANCER DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 ($ MILLIONS)
  • NEXT GENERATION CANCER DIAGNOSTIC REGIONAL MARKET
  • TABLE 91 GLOBAL NEXT GENERATION CANCER DIAGNOSTIC BY REGION, THROUGH 2019 ($ MILLIONS)

CHAPTER 8 PATENTS

  • MICROARRAY PATENTS
  • TABLE 92 DNA MICROARRAY-RELATED PATENTS BY REGION, 2002-2012
  • TABLE 93 MICROARRAY-RELATED PROTEOMICS PATENTS BY REGION, 2002-2012
  • LAB-ON-A-CHIP PATENTS
  • TABLE 94 LAB-ON-A-CHIP-RELATED PROTEOMIC PATENTS BY REGION, 2002-2012
  • RT-PCR PATENTS
  • TABLE 95 ISSUED RT-PCR-RELATED PATENTS BY REGION, 2002-2012
  • CIRCULATING TUMOR CELL PATENTS
  • TABLE 96 ISSUED CIRCULATING TUMOR CELL-RELATED PATENTS BY REGION, 2002-2012
  • CLINICAL NEXT GENERATION SEQUENCING PATENTS
  • TABLE 97 CLINICAL NEXT GENERATION SEQUENCING-RELATED SEQUENCING PATENTS, 2002-2012
  • CLINICAL NEXT GENERATION SEQUENCING PATENTS BY INDICATION
  • TABLE 98 CLINICAL NEXT GENERATION SEQUENCING-RELATED PATENTS BY INDICATION, 2002-2012

CHAPTER 9 COMPANY PROFILES

  • 20/20 GENE SYSTEMS INC.
  • ABBOTT LABORATORIES
  • ABTECH SCIENTIFIC INC.
  • ADAPTIVE BIOTECHNOLOGIES INC.
  • ADNAGEN GMBH
  • ADVANCED CELL DIAGNOSTICS INC.
  • AFFYMETRIX INC.
  • AGENDIA NV
  • TABLE 99 AGENDIA MICROARRAY-BASED DIAGNOSTICS PIPELINE, 2014
  • AGILENT TECHNOLOGIES INC.
  • ALLEGRO DIAGNOSTICS INC.
  • ALMAC GROUP LTD.
  • AMBRY GENETICS
  • APPISTRY INC.
  • ARPEGGI INC.
  • ARRAYIT CORP.
  • ASTRID BIOSCIENCE GMBH
  • ASURAGEN INC.
  • AUTOGENOMICS INC.
  • AXELA BIOSENSORS
  • AYANDA BIOSYSTEMS SA
  • BGI
  • BIOCARTIS SA
  • BIOCEPT INC.
  • TABLE 100 CANCERS
  • BIODESIX INC.
  • BIOLOGICAL DYNAMICS INC.
  • BIOTHERANOSTICS
  • BIOTIME INC.
  • BOREAL GENOMICS
  • CANCER GENETICS INC.
  • CARIS LIFE SCIENCES
  • CASTLE BIOSCIENCES INC.
  • CEPHEID
  • CHRONIX BIOMEDICAL INC.
  • CIRCADIAN TECHNOLOGIES
  • COMBIMATRIX MOLECULAR DIAGNOSTICS INC.
  • CVERGENX
  • DECODE GENETICS
  • DIAGNOPLEX SA
  • DIAXONHIT
  • EPIC SCIENCES INC.
  • EXACT SCIENCES CORP.
  • EXIQON A/S
  • EXOSOME SCIENCES INC.
  • EXOSOME DIAGNOSTICS INC.
  • EVENTUS DIAGNOSTICS INC.
  • FOUNDATION MEDICINE
  • FUSION GENOMICS CORP.
  • GATC BIOTECH AG
  • GE HEALTHCARE
  • GENALYTE INC.
  • GENEDX INC.
  • GENENEWS
  • GENERA BIOSYSTEMS LIMITED
  • GENETIC TECHNOLOGIES LTD.
  • GENOMIC HEALTH INC.
  • GIGAGEN INC.
  • GUARDANT HEALTH INC.
  • HEALTHLINX LIMITED
  • HOLOGIC INC.
  • HUMAN LONGEVITY INC.
  • ILLUMINA INC.
  • INSIGHT GENETICS INC.
  • INTEGRAGEN SA
  • INVITAE
  • IRIS BIOTECHNOLOGIES INC.
  • IRIS INTERNATIONAL INC.
  • JOHNSON & JOHNSON
  • LABORATORY CORP. OF AMERICA INC.
  • LABORATORY FOR MOLECULAR MEDICINE
  • LIFE TECHNOLOGIES INC.
  • MAGARRAY INC.
  • MAVEN BIOTECHNOLOGIES
  • MD ANDERSON CANCER CENTER
  • MDX HEALTH S.A.
  • MED BIOGENE INC.
  • MEDGENOME LABS PVT. LTD.
  • METAMARK GENETICS INC.
  • MINGYUAN MEDICARE DEVELOPMENT COMPANY LTD.
  • MIRA DX
  • MITOMICS INC.
  • MYRIAD GENETICS INC.
  • NANOIVD INC.
  • NANOSTRING TECHNOLOGIES INC.
  • NATURALNANO INC.
  • NEOGENOMICS LABORATORIES
  • NEWGENE LIMITED
  • TABLE 101 NEWGENE CANCER TESTS
  • NEXUS DX INC.
  • NOVARTIS AG
  • NUCLEA BIOTECHNOLOGIES INC.
  • NUVERA BIOSCIENCES
  • ONCODNA SA
  • ONCOLYS BIOPHARMA INC.
  • ONCOSPIRE GENOMICS
  • OPKO HEALTH INC.
  • OXFORD GENE TECHNOLOGY
  • PARADIGM
  • PERKIN ELMER INC.
  • PERSONAL GENOME DIAGNOSTICS
  • PGXL LABORATORIES
  • PHILIPS ELECTRONICS NV
  • PHYSICIAN'S CHOICE LABORATORY SERVICES
  • PREVENTIONGENETICS INC.
  • QIAGEN
  • QIAGEN MARSEILLE
  • QUANTUMDX
  • QUEST DIAGNOSTICS
  • RAINDANCE TECHNOLOGIES INC.
  • RANDOX LABORATORIES, LTD.
  • RESPONSE GENETICS INC.
  • RHEONIX
  • ROCHE HOLDING AG
  • ROSETTA GENOMICS INC.
  • TABLE 102 ROSETTA'S DIAGNOSTIC TESTS, 2014
  • SEQUENTA INC.
  • SIGNAL GENETICS LLC
  • SIGNATURE DIAGNOSTICS AG
  • SISTEMAS GENOMICOS, SL
  • SKYLINEDX B.V.
  • SOFTGENETICS LLC
  • SOMALOGIC INC.
  • STRAND LIFE SCIENCES
  • SYAPSE
  • SYSMEX CORP.
  • THERMO FISHER SCIENTIFIC INC.
  • TRANSGENOMIC INC.
  • TROVAGENE INC.
  • VERACYTE
  • VERISANTE TECHNOLOGY INC.
  • VITATEX INC.
  • VOLITIONRX LTD.
  • XAGENIC INC.

LIST OF TABLES

  • SUMMARY TABLE GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
  • TABLE 1 REPORT SCOPE
  • TABLE 2 GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 ($ MILLIONS)
  • TABLE 3 CANCER DIAGNOSTIC MARKET DRIVING FORCES, THROUGH 2019
  • TABLE 4 DIAGNOSTIC PRODUCT LIFECYCLE STATUS, 2014
  • TABLE 5 NEXT GENERATION CANCER DIAGNOSTIC INDUSTRY, 2014
  • TABLE 6 DIAGNOSTIC MARKET SEGMENTS
  • TABLE 7 NEXT GENERATION CANCER DIAGNOSTIC PLATFORMS, 2014-2019
  • TABLE 8 ANALYSIS PLATFORMS AND BIOMARKER TYPES
  • TABLE 9 SCOPE OF KEY GENOMIC ANALYSIS TECHNOLOGIES, 2014
  • TABLE 10 GENETIC ANALYSIS TECHNOLOGY PLATFORM COMPARISON
  • TABLE 11 EPIGENETICS WITHIN THE MOLECULAR BIOLOGY PARADIGM
  • TABLE 12 CIRCULATING TUMOR CAPTURE METHODS
  • TABLE 13 CIRCULATING TUMOR CAPTURE IDENTIFICATION METHODS
  • TABLE 14 DNA MICROARRAY TECHNOLOGIES
  • TABLE 15 PROTEIN MICROARRAY PLATFORMS
  • TABLE 16 LAB-ON-A-CHIP TYPES
  • TABLE 17 CONVENTIONAL END-POINT REAL-TIME POLYMERASE CHAIN REACTION DETECTION PROBLEMS
  • TABLE 18 REAL-TIME POLYMERASE CHAIN REACTION CANCER DIAGNOSTIC APPLICATIONS
  • TABLE 19 NEXT GENERATION SEQUENCING TECHNOLOGIES
  • TABLE 20 ROCHE NEXT GENERATION SEQUENCING WORKFLOW, 2014
  • TABLE 21 ILLUMINA NEXT GENERATION SEQUENCING WORKFLOW, 2014
  • TABLE 22 LIFE TECHNOLOGIES NEXT GENERATION SEQUENCING WORKFLOW, 2014
  • TABLE 23 BENCHTOP SEQUENCER PLATFORMS, 2014
  • TABLE 24 GENETIC TESTING EVOLUTION
  • TABLE 25 KEY NEAR- TO MID-TERM SEGMENTS FOR NEXT GENERATION SEQUENCING DIAGNOSTICS, 2014-2019
  • TABLE 26 NEXT GENERATION DIAGNOSTIC PARADIGM SHIFT, 2000-2020
  • TABLE 27 BIOMARKERS USED IN NEXT GENERATION DIAGNOSTICS
  • TABLE 28 DNA MICROARRAY DIAGNOSTIC TEST ADOPTION RATE
  • TABLE 29 COMPARISON OF DNA-BASED MDX PLATFORMS
  • TABLE 30 FACTORS AFFECTING PENETRATION OF NEXT GENERATION FORMATS INTO THE MDX MARKET
  • TABLE 31 U.S. INCIDENCE AND DEATHS FOR SELECTED CANCERS, 2010 AND 2013 (NUMBER)
  • TABLE 32 BLADDER CANCER NEXT GENERATION DIAGNOSTIC TESTS, 2014
  • TABLE 33 BRAIN CANCER NEXT GENERATION DIAGNOSTIC TESTS, 2014
  • TABLE 34 U.S. ANNUAL BREAST CANCER TREATMENT DECISIONS BY CANCER CLASSIFICATION, 2014 (NUMBER)
  • TABLE 35 BREAST CANCER MDX TECHNOLOGY PLATFORMS, 2014
  • TABLE 36 NEXT GENERATION BREAST CANCER TESTS, 2014
  • TABLE 37 NEXT GENERATION HUMAN PAPILLOMA VIRUS AND CERVICAL CANCER TESTS, 2014
  • TABLE 38 COLORECTAL CANCER SCREENING AND DIAGNOSTIC TESTS, 2014
  • TABLE 39 NEXT GENERATION DIAGNOSTIC TESTS FOR COLORECTAL CANCER, 2014
  • TABLE 40 CANCER OF UNKNOWN PRIMARY NEXT GENERATION DIAGNOSTIC TESTS, 2014
  • TABLE 41 GASTRIC AND STOMACH CANCER NEXT GENERATION DIAGNOSTIC TESTS, 2014
  • TABLE 42 NEXT GENERATION KIDNEY CANCER DIAGNOSTIC TESTS, 2014
  • TABLE 43 NEXT GENERATION LEUKEMIA AND MYELOMA DIAGNOSTIC TESTS, 2014
  • TABLE 44 NEXT GENERATION LIVER CANCER DIAGNOSTIC TESTS, 2014
  • TABLE 45 FIVE-YEAR SURVIVAL RATES FOR NON-SMALL CELL LUNG CANCER, 2014 (%)
  • TABLE 46 NEXT GENERATION LUNG CANCER DIAGNOSTIC TESTS, 2014
  • TABLE 47 NEXT GENERATION LYMPHOMA CANCER DIAGNOSTIC TESTS, 2014
  • TABLE 48 NEXT GENERATION MELANOMA DIAGNOSTIC TESTS, 2014
  • TABLE 49 OVARIAN CANCER EARLY SCREENING TESTS
  • TABLE 50 NEXT GENERATION OVARIAN CANCER DIAGNOSTIC TESTS, 2014
  • TABLE 51 NEXT GENERATION PAN-CANCER DIAGNOSTIC TESTS, 2014
  • TABLE 52 NEXT GENERATION PANCREATIC CANCER DIAGNOSTIC TESTS, 2014
  • TABLE 53 NEXT GENERATION PROSTATE CANCER DIAGNOSTIC TESTS, 2014
  • TABLE 54 NEXT GENERATION THYROID CANCER DIAGNOSTIC TESTS, 2014
  • TABLE 55 NEXT GENERATION DIAGNOSTIC TEST SUMMARY BY INDICATION AND TECHNOLOGY, 2014
  • TABLE 56 ACQUISITIONS IN NEXT GENERATION CANCER DIAGNOSTICS INDUSTRY, 2012-2014
  • TABLE 57 NEXT GENERATION CANCER DIAGNOSTIC STRATEGIC ALLIANCES, 2012-2014
  • TABLE 58 CIRCULATING TUMOR CELL INDUSTRY, 2014
  • TABLE 59 DNA MICROARRAY INDUSTRY, 2014
  • TABLE 60 NEXT GENERATION SEQUENCING INSTRUMENT COMPANIES: COMMERCIAL PHASE, 2014
  • TABLE 61 LEADING U.S. CLINICAL LABORATORY IMPROVEMENT AMENDMENTS LABORATORIES WITH NEXT-GENERATION SEQUENCING DIAGNOSTICS, 2014
  • TABLE 62 NEXT GENERATION LAB-ON-A-CHIP CANCER DIAGNOSTIC INDUSTRY, 2014
  • TABLE 63 NEXT GENERATION RT-PCR CANCER DIAGNOSTIC INDUSTRY, 2014
  • TABLE 64 CANCER DIAGNOSTIC MARKET DRIVING FORCES, 2014-2019
  • TABLE 65 GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 ($ MILLIONS)
  • TABLE 66 GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY ANALYSIS TYPE, THROUGH 2019 ($ MILLIONS)
  • TABLE 67 GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
  • TABLE 68 GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY FUNCTION, THROUGH 2019 ($ MILLIONS)
  • TABLE 69 GLOBAL DNA MICROARRAY CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
  • TABLE 70 GLOBAL PROTEIN MICROARRAY CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
  • TABLE 71 GLOBAL LAB-ON-A-CHIP CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
  • TABLE 72 GLOBAL RT-PCR CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
  • TABLE 73 GLOBAL NEXT GENERATION SEQUENCING CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
  • TABLE 74 GLOBAL NEXT GENERATION CAPTURE CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
  • TABLE 75 GLOBAL MULTIPLEX CONVENTIONAL CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
  • TABLE 76 GLOBAL NEXT GENERATION CANCER RISK MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
  • TABLE 77 GLOBAL NEXT GENERATION CANCER SCREENING MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
  • TABLE 78 GLOBAL NEXT GENERATION CANCER PROGNOSTIC MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
  • TABLE 79 GLOBAL NEXT GENERATION CANCER MONITORING MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
  • TABLE 80 GLOBAL NEXT GENERATION CANCER COMPANION DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
  • TABLE 81 GLOBAL NEXT GENERATION BREAST CANCER DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 ($ MILLIONS)
  • TABLE 82 GLOBAL NEXT GENERATION CERVICAL CANCER DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 ($ MILLIONS)
  • TABLE 83 GLOBAL NEXT GENERATION COLORECTAL CANCER DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 ($ MILLIONS)
  • TABLE 84 GLOBAL NEXT GENERATION CANCER OF UNKNOWN PRIMARY (CUP) DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 ($ MILLIONS)
  • TABLE 85 GLOBAL NEXT GENERATION LEUKEMIA DIAGNOSTIC MARKET BY TECHNOLOGY FORMAT, THROUGH 2015 ($ MILLIONS)
  • TABLE 86 GLOBAL NEXT GENERATION LUNG CANCER DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 ($ MILLIONS)
  • TABLE 87 GLOBAL NEXT GENERATION LYMPHOMA DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 ($ MILLIONS)
  • TABLE 88 GLOBAL NEXT GENERATION PAN-CANCER DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 ($ MILLIONS)
  • TABLE 89 GENOME COVERAGE OF REPRESENTATIVE NEXT GENERATION SEQUENCING PAN-CANCER TESTS, 2014
  • TABLE 90 GLOBAL NEXT GENERATION PROSTATE CANCER DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 ($ MILLIONS)
  • TABLE 91 GLOBAL NEXT GENERATION CANCER DIAGNOSTIC BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 92 DNA MICROARRAY-RELATED PATENTS BY REGION, 2002-2012
  • TABLE 93 MICROARRAY-RELATED PROTEOMICS PATENTS BY REGION, 2002-2012
  • TABLE 94 LAB-ON-A-CHIP-RELATED PROTEOMIC PATENTS BY REGION, 2002-2012
  • TABLE 95 ISSUED RT-PCR-RELATED PATENTS BY REGION, 2002-2012
  • TABLE 96 ISSUED CIRCULATING TUMOR CELL-RELATED PATENTS BY REGION, 2002-2012
  • TABLE 97 CLINICAL NEXT GENERATION SEQUENCING-RELATED SEQUENCING PATENTS, 2002-2012
  • TABLE 98 CLINICAL NEXT GENERATION SEQUENCING-RELATED PATENTS BY INDICATION, 2002-2012
  • TABLE 99 AGENDIA MICROARRAY-BASED DIAGNOSTICS PIPELINE, 2014
  • TABLE 100 CANCERS
  • TABLE 101 NEWGENE CANCER TESTS
  • TABLE 102 ROSETTA'S DIAGNOSTIC TESTS, 2014

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY INDICATION, 2013-2019 ($ MILLIONS)
  • FIGURE 1 DNA, MRNA AND GENETIC VARIATION
  • FIGURE 2 EPIGENETIC CHANGES TO DNA AFFECTING GENE EXPRESSION
  • FIGURE 3 SENSITIVITY AND SPECIFICITY
Back to Top